XORTX Therapeutics Inc.
XRTX · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D44Loss-making clinical-stage biotech on stale FY2021 data needing continual financing.
Strengths
- Very high current ratio (28.8, 98th pct) and ~$14.7M cash at the period
- Active FDA/NDA pathway for XORLO (gout, ADPKD) programs
Risks
- Negative returns (ROA -7.5%, ROE -9.9%), accumulated deficit ~$24M and recurring dilution/share consolidations
- Nasdaq minimum-bid issues and ongoing going-concern-type funding dependence
Key metrics
Return on equity
-9.9%
Return on assets
-7.5%
Current ratio
28.8×
Tangible book value
$13M
Cash & investments
$15M
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-20 | 2025-12-31 | 0001104659-26-032775 ↗ |
| 20-F | 2025-05-12 | 2024-12-31 | 0001410578-25-001183 ↗ |
| 20-F | 2024-05-10 | 2023-12-31 | 0001410578-24-000737 ↗ |
| 20-F | 2023-04-28 | 2022-12-31 | 0001410578-23-000844 ↗ |
| 20-F | 2022-05-03 | 2021-12-31 | 0001753926-22-000646 ↗ |